Ant International’s Alipay+ Enables Mobile Payments for Global Travellers in Latin America
26.5.2026 12:40:00 EEST | Business Wire | Press release
Alipay+, a leading global payment gateway under Ant International that connects 150 million global merchants and 2 billion consumer accounts, is rolling out cross-border mobile payment services for global travellers in Latin America in collaboration with PVS, a fintech company specialized in developing customized payment solutions in the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526146133/en/
Facilitated by Alipay+ and PVS, travellers from Asia and Europe can now use their familiar home e-wallets and banking apps to make QR code payments at PVS merchants, starting with initial rollouts in Chile and Argentina.
This partnership enables users of Alipay+’s partner payment apps, including 50 e-wallets and banking apps, and over 10 national QR schemes, to make seamless QR payments at PVS merchants. The collaboration aims to support global travellers, especially those from Asia who are increasingly exploring multiple destinations and planning longer stays in the region, with convenience, transparency, security and zero currency exchange pains. Coverage begins with Chile and Argentina and will expand to other markets.
Through one single integration, businesses large and small can receive payments in local currency with minimal friction from leading wallets and banking apps in Asia and Europe. Merchants will also be able to leverage cross-border digital user engagement and marketing opportunities, as Alipay+ rolls out more AI-powered travel solutions for its ecosystem.
“At PVS, we are proud to partner with Alipay+ to offer Asian and European travellers visiting Latin America a payment experience that is familiar, secure and transparent, through the wallets they already know and trust,” said Lucio Colunga, CEO, PVS. “This partnership also reinforces our commitment to connecting local businesses with international consumers, helping merchants capture new growth opportunities across the region.”
“This landmark partnership builds on Ant International’s technology capabilities, risk solutions and marketing tools with PVS's deep local expertise, fast-growing networks and regulatory know-how,” said Weixiao Jiang, General Manager for North Asia and the Americas, Alipay+, Ant International. "We are deeply committed to expanding public and private partnerships to contribute to the regional digitalization and AI agendas.”
With an average of over 20 million transactions daily, Ant International is a leading global digital payment, digitisation and financial technology provider. It supports financial institutions and merchants of all sizes across Asia, Europe, Middle East and the Americas with a comprehensive suite of solutions, ranging from payment and account services to digitisation, embedded finance, treasury management and other AI-powered financial innovations.
For example, Alipay+ NFC (near-field communication) enables cross-border transactions through its partnership with Mastercard. Starting with AlipayHK, GCash and Kakao Pay, users can now make NFC payments at over 150 million Mastercard-enabled merchants worldwide, including across Argentina, Brazil, Mexico and other Latin American markets.
In Latin America, Ant International is expanding partnerships with more global and local payment service providers, as well as fintech companies and digital platforms to provide cross-border payment and credit services for SMEs and individuals. This includes Ant International's collaboration with R2, a leading embedded lending infrastructure company headquartered in Mexico, to expand SME financing across the region.
In May 2025, Ant International became the Argentina National Football Team’s official sponsor for the Asia region (excluding the Middle East).
About Alipay+
Ant International's Alipay+ is a unified wallet gateway with cross-border payment and digitisation services that help connect global merchants to consumers. Consumers enjoy seamless payments a broad choice of deals and the convenience of digital services using their preferred payment app/e-wallet while travelling abroad. Many small and medium-sized businesses already use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260526146133/en/
Contacts
Media Contacts
Ant International
pr@ant-intl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom